MEDIUS HOLDINGS (3154) FY2026 Q2 Earnings Report

Quick View

Executive Summary

Despite higher revenue, the Company posted a decline in revenue and earnings, as its heavy SG&A burden under a low gross-margin structure prevented a return to operating income growth. Revenue was ¥149.21B (+4.6% year on year), Operating Income was ¥0.58B (-22.1%), Ordinary Income was ¥0.82B (-16.9%), and Net Income was ¥0.39B (-4.6%). With an SG&A ratio of 11.2% against a gross margin of 11.6%, limited operating leverage remained, and the increase in revenue was insufficient to absorb the increase in expenses. First-half progress against the full-year forecast was 48.9% for Revenue versus 33.4% for Operating Income, indicating delayed earnings progress.

Factors Affecting Results

【Revenue】Revenue increased 4.6% year on year to ¥149.21B. By segment, the core Medical Equipment Sales Business generated ¥146.09B (97.9% of total), while the Nursing Care and Welfare Business generated ¥3.13B (2.1%). Expansion of medical equipment sales drove the overall increase in revenue.

【Profit and Loss】Operating Income declined 22.1% year on year to ¥0.58B, Ordinary Income declined 16.9% to ¥0.82B, and Net Income declined 4.6% to ¥0.39B. The Operating Income margin was 3.1% for the Medical Equipment Sales Business and 9.8% for the Nursing Care and Welfare Business; however, corporate expenses of ¥0.44B, including ¥0.15B in amortization of goodwill, weighed on segment earnings, reducing the consolidated Operating Income margin to 0.4%. Ordinary Income exceeded Operating Income due to net non-operating income of ¥0.23B, including ¥0.03B in dividend income. Against Profit Before Tax of ¥0.80B, income taxes of ¥0.42B resulted in a high effective tax rate of 51.7%, restraining the conversion to Net Income. Extraordinary income of ¥0.01B and extraordinary loss of ¥0.02B were immaterial, and the impact of temporary factors was limited. Revenue increased, but earnings declined.

Segment Analysis

The Medical Equipment Sales Business is the core business, accounting for 97.9% of total company revenue, with revenue of ¥146.09B and Operating Income of ¥4.51B (3.1% margin). The Nursing Care and Welfare Business is smaller, with revenue of ¥3.13B and Operating Income of ¥0.31B (9.8% margin), but has a relatively higher profit margin. Against combined segment earnings of ¥4.82B, corporate expenses of ¥0.44B, including ¥0.15B in goodwill amortization, were recorded, compressing consolidated Operating Income to ¥0.58B. The corporate expense burden is heavy relative to segment earnings power and is the primary cause of the decline in the consolidated profit margin.

Key Financial Indicators

【Profitability】The Operating Income margin of 0.4% and Net Income margin of 0.3% were both low. With an SG&A ratio of 11.2% against a gross margin of 11.6%, the earnings structure had limited operating capacity. The effective tax rate was high at 51.7%, restraining the conversion of Profit Before Tax of ¥0.80B into Net Income of ¥0.39B.【Cash Flow Quality】Operating Cash Flow (OCF) was -¥1.63B, and the OCF/Net Income ratio was negative against Net Income of ¥0.39B, indicating that current-period earnings had not been converted into cash. The primary factors were increases of ¥8.19B in trade receivables and ¥1.39B in inventories, partially offset by a ¥7.84B increase in trade payables.【Investment Efficiency】ROE was 1.9% (cumulative). Capital expenditures of ¥0.32B were below depreciation and amortization of ¥0.92B, indicating restrained replacement investment.【Financial Soundness】The Equity Ratio was 15.9%, down from approximately 17.0% in the previous year. While total assets expanded to ¥127.64B, net assets remained broadly flat at ¥20.28B, indicating that the asset expansion was funded primarily by liabilities, including increased short-term borrowings.

Cash Flow Analysis

OCF deteriorated significantly to -¥1.63B from +¥1.48B in the previous year, as working capital expansion associated with higher revenue placed pressure on cash. Trade receivables increased by ¥8.19B and inventories increased by ¥1.39B, while the ¥7.84B increase in trade payables provided a partial offset; nevertheless, OCF remained negative. Investing Cash Flow was -¥0.61B, including capital expenditures of ¥0.32B, resulting in Free Cash Flow of -¥2.23B. Financing Cash Flow was +¥7.15B, as the net increase in short-term borrowings covered the funding shortfall from operating and investing activities, increasing cash and cash equivalents by ¥4.92B. The increase in cash during the period was characterized not by internally generated cash, but by reliance on debt financing.

Earnings Quality

Current-period earnings were only minimally affected by extraordinary items—extraordinary income of ¥0.01B and extraordinary loss of ¥0.02B—and were primarily generated by recurring business operations. Ordinary Income of ¥0.82B comprised Operating Income of ¥0.58B plus net non-operating income of ¥0.23B, including ¥0.03B in dividend income. Reliance on non-operating income remained approximately 0.3% of revenue and was not at a level capable of materially affecting the earnings structure. However, the high effective tax rate of 51.7% weakened the conversion of Profit Before Tax into Net Income. Comprehensive Income was ¥0.24B, below Net Income of ¥0.39B, primarily due to a -¥0.15B change in the valuation difference on securities. In addition, OCF of -¥1.63B was substantially below Net Income, and the deterioration in working capital caused by increases in trade receivables and inventories created an accrual-based divergence between earnings and cash. Accordingly, earnings quality remains an area with room for improvement.

Earnings Forecasts and Guidance

First-half progress against the full-year forecast was 48.9% for Revenue, 33.4% for Operating Income, 35.5% for Ordinary Income, and 29.8% for Net Income. Revenue was progressing broadly in line with a standard first-half pace, but earnings progress was substantially below the 50% benchmark. The full-year forecast itself anticipates year-on-year declines in both Operating Income and Ordinary Income (-6.7% and -5.1%, respectively), indicating that the Company’s plan already incorporates lower profitability. To achieve the full-year Operating Income forecast of ¥1.75B, the second half will require approximately ¥1.17B of Operating Income, roughly twice the first-half result of ¥0.58B. A recovery in profitability through improved gross margins or greater SG&A efficiency will therefore be a key monitoring point.

Shareholder Returns

The dividend as of the end of Q2 was ¥0, while the full-year dividend forecast is ¥20 per share. Based on the full-year Net Income forecast of ¥1.30B, the Payout Ratio is approximately 34.2%, below the 60% level generally regarded as a sustainability benchmark when considering dividends alone. However, first-half Free Cash Flow was -¥2.23B, and the first-half dividend payment of ¥0.44B was effectively supplemented by Financing Cash Flow, or borrowings, rather than internally generated cash. Dividend sustainability will depend on improvements in second-half OCF and achievement of the full-year earnings forecast.

Risk Factors

1. Low-Margin Structure Risk: Given the thin-margin structure, with a gross margin of 11.6% and an Operating Income margin of 0.4%, even small fluctuations in procurement prices, logistics expenses, and labor costs could materially affect earnings. The current-period results, in which Revenue increased 4.6% while Operating Income declined 22.1%, demonstrate this sensitivity.

2. Working Capital and Leverage Risk: OCF was -¥1.63B and Free Cash Flow was -¥2.23B, with the net increase in short-term borrowings (Financing Cash Flow of +¥7.15B) covering the funding shortfall. The Equity Ratio was 15.9%, and short-term borrowings of ¥24.82B exceeded cash and deposits of ¥19.25B, indicating high sensitivity to changes in the financing environment.

3. Credit and Inventory Risk: The Company held trade receivables of ¥66.16B, equivalent to 51.8% of total assets, and inventories of ¥14.99B. During the period, these balances increased by ¥8.19B and ¥1.39B, respectively. Changes in customer payment terms or deterioration in inventory valuation could affect liquidity and earnings.

Industry Benchmark (For Reference; Company Compilation)

Industry Benchmark (trading)

Profitability and Returns

The Net Income margin was 6.7pt below the industry median, positioning the Company among the lower-profitability companies in the industry.

Growth and Capital Efficiency

The Revenue growth rate was broadly in line with the industry median, indicating an industry-standard pace of revenue growth.

※Source: Company compilation

Key Takeaways from the Results

1. While Revenue increased 4.6%, the Operating Income margin declined from the previous year. Going forward, the focus should be placed less on the Revenue growth rate and more on expanding gross profit and improving the ability to absorb SG&A expenses.

2. First-half progress against the full-year Operating Income forecast was only 33.4%, meaning that the plan requires approximately twice the first-half Operating Income to be secured in the second half.

3. While OCF was -¥1.63B, short-term borrowings increased on a net basis. The conversion of earnings into cash—through collection of trade receivables and inventory management—will be a key focus of the financial structure in the second half.

Theoretical Share Price (Reference Value)

Sensitivity: ¥846–¥895 at ±1% for the Cost of Equity, and ¥869–¥871 at ±0.1 for ω.

Notes:

• Goodwill amortization of ¥13.5 per share is added back to earnings (due to its non-cash nature and for comparability with IFRS companies).
• Because forecast ROE is below the Cost of Equity, the theoretical value is below Book Value per Share.
• Net assets as of the quarter-end are used (there is a timing difference from the full-year forecast).
• Because net assets include non-controlling interests, the theoretical value may be calculated somewhat higher.

(Calculation model: Residual Income Model (Ohlson-type; explicit 5-year fade) / Interest rate reference month: 2026-07 / Mechanically calculated solely from publicly disclosed data; this is not a forecast of the market share price or a recommendation of any specific investment action, nor does it forecast or guarantee future share prices.)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings summary data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own discretion and responsibility, after consulting with a professional as necessary.

---End of Report---

---

AI Financial Analysis

Executive Summary

FY2026 Q2 results were weak in profitability and cash conversion despite continued top-line growth. Revenue rose 4.6% YoY to ¥149.21bn, reaching 48.9% of the ¥305.0bn full-year sales forecast, broadly in line with the 50% first-half seasonal benchmark. Gross profit increased only 2.7% to ¥17.33bn, lagging revenue growth. Consequently, the gross margin contracted by 23bp YoY to 11.6%. SG&A expenses increased 3.8% to ¥16.74bn, below revenue growth but still absorbing 96.6% of gross profit. Operating income declined 22.1% to ¥0.585bn. The operating margin compressed by approximately 13bp YoY to 0.39%, underscoring the limited ability of the distribution model to absorb gross-margin pressure. Ordinary income declined 16.9% to ¥0.817bn, while profit attributable to owners fell a more limited 4.8% to ¥0.387bn. The net margin was only 0.26%, down roughly 2bp YoY. Non-operating income of ¥0.383bn supported ordinary income, including ¥0.251bn of dividend income, but it did not offset the operating-profit decline. The effective tax rate was elevated at 51.7%, reducing the tax burden factor to 0.482. Operating cash flow was negative ¥1.628bn versus positive net income of ¥0.387bn, producing an OCF/net income ratio of negative 4.21x. The cash-flow deficit principally reflected a ¥8.185bn increase in receivables and a ¥1.386bn increase in inventories, only partly financed by a ¥7.839bn increase in trade payables. Free cash flow was negative ¥2.233bn after ¥0.318bn of capital expenditure. Financing cash flow of ¥7.149bn, led by an ¥8.131bn increase in short-term loans, funded the cash increase rather than internally generated cash. Full-year operating-income progress is only 33.4%, 16.6 percentage points below the normal 50% Q2 pace, while ordinary-income progress is 35.5% and attributable-profit progress is 29.8%. The company therefore requires a substantial second-half recovery in margins, working-capital conversion and earnings execution to achieve guidance. Goodwill exposure itself is modest, but high balance-sheet leverage and the short maturity profile remain central constraints on financial flexibility.

Profitability Analysis

The reported annualized ROE of 3.8% is decomposed into a 0.3% net profit margin, 2.338x asset turnover and 6.29x financial leverage. The key source of the low ROE is the exceptionally thin margin rather than poor asset turnover; high leverage is supporting, rather than reflecting, underlying shareholder returns. Revenue growth of 4.6% did not translate into gross-profit growth, which rose only 2.7%, indicating gross-margin pressure. Gross margin declined to 11.6% from approximately 11.8% in the prior-year period. Operating margin fell to 0.39% from approximately 0.53%, a compression of about 13bp. SG&A rose 3.8%, slower than revenue, so the primary earnings pressure appears to be at the gross-profit level rather than excess overhead growth. Salaries and allowances rose to ¥6.82bn from ¥6.60bn, while rent expense increased to ¥1.25bn from ¥1.20bn, leaving limited scope for these fixed and semi-fixed costs to be covered when gross-profit growth slows. EBITDA declined to ¥1.505bn from approximately ¥1.607bn, and EBITDA margin fell to 1.0%. JGAAP goodwill amortization was ¥0.150bn, or 9.9% of EBITDA, a meaningful but not material cross-standard distortion; EBITDA before goodwill amortization was ¥1.655bn. Interest expense increased to ¥0.103bn from ¥0.075bn as borrowings expanded, although EBITDA interest coverage remained 14.65x and EBIT interest coverage was 5.69x. The 5-factor DuPont interest-burden figure exceeds 1.0 because profit before tax exceeded operating income due to net non-operating income; this should not be interpreted as evidence that debt costs are immaterial. The elevated effective tax rate of 51.7% reduced conversion from pre-tax profit to net income. The current margin structure is not robust: a small change in procurement terms, reimbursement conditions, sales mix or logistics costs can have a disproportionate effect on operating profit. Sustained recovery requires gross-margin stabilization and preservation of SG&A discipline, since current leverage leaves little room for operating underperformance.

Growth Assessment

Sales growth remained positive at 4.6% YoY, but earnings growth was negative across operating income, ordinary income and net income. The divergence between revenue and operating profit indicates that the incremental sales generated lower profitability than the existing business mix. Revenue progress of 48.9% is near the normal first-half run rate for the full-year forecast. In contrast, operating-income progress is 33.4% versus the normal 50%, a 16.6 percentage-point shortfall. Ordinary income progress is 35.5%, 14.5 percentage points below the standard pace, and attributable-profit progress is 29.8%, 20.2 percentage points below it. The full-year forecast implies second-half revenue of ¥155.79bn, up 4.4% from first-half revenue, but requires operating income of ¥1.165bn, almost twice first-half operating income. It also requires attributable profit of ¥0.913bn, 2.4x first-half attributable profit. This profile points to a heavily back-end-loaded earnings plan and makes margin recovery the key determinant of forecast delivery. Net non-operating income supported ordinary income, but operating performance remains the more relevant indicator of recurring earnings capacity. The modest ¥0.038bn net extraordinary loss had limited influence on the earnings trend. Fixed-asset impairment totaled ¥0.038bn, concentrated in the medical-device sales business at ¥0.036bn, with ¥0.002bn in the care and welfare business; the absolute amount is small, but it warrants monitoring as an indicator of asset-level returns. One subsidiary was newly consolidated and one was excluded from consolidation during the period, which may modestly affect comparability and sales mix. The business's high-volume, low-margin distribution characteristics make revenue growth alone an insufficient indicator of value creation. The second-half outlook depends on restoring gross-profit conversion while preventing receivables and inventory from consuming further cash.

Financial Health

Financial health is constrained by aggressive leverage and substantial reliance on short-term funding. The current ratio is 107.9%, above 1.0x, so current assets nominally cover current liabilities; however, it remains below the 1.5x level generally associated with strong liquidity. The quick ratio is 92.4%, below 1.0x, meaning liquid assets excluding inventories do not fully cover current liabilities. Working capital was positive at ¥7.674bn, but its protection is limited by the scale of receivables and inventory relative to short-term obligations. Current liabilities were ¥96.69bn, including ¥24.82bn of short-term loans and ¥67.95bn of trade payables. Short-term loans increased ¥8.06bn, or 48.1% YoY, to ¥24.82bn. Cash and deposits increased ¥4.92bn, or 34.3% YoY, to ¥19.25bn, but the increase was funded primarily by financing activities rather than operating cash generation. The cash-to-short-term-debt ratio was 0.78x, leaving a portion of near-term borrowings dependent on operating cash collection, payables management or refinancing. Short-term debt represents 86.0% of interest-bearing debt, creating a material maturity mismatch risk given the negative operating cash flow in the period. The debt-to-equity ratio of 5.29x is well above the 2.0x warning threshold and is a direct financial-risk concern. Debt/EBITDA of 19.18x is also high, reflecting both elevated debt and a low EBITDA base. Debt/capital was 58.7%, close to the 60% caution threshold. Interest coverage remains acceptable at 5.69x on EBIT and 14.65x on EBITDA, but the EBIT measure has reduced headroom if margin pressure persists. Total equity declined to ¥20.29bn from ¥20.48bn despite positive attributable profit, principally consistent with adverse comprehensive-income movements. Total comprehensive income was ¥2.43bn, below attributable profit, with a negative ¥1.45bn other comprehensive-income movement. Goodwill was only ¥1.05bn, equal to 5.2% of equity and 0.8% of assets, so the balance sheet is not materially dependent on M&A valuation retention. No material off-balance-sheet obligations are identified in the provided financial information.

Notable B/S Changes

Short-term loans: +¥8.06bn (+48.1%) to ¥24.82bn - borrowing increased sharply and funded liquidity while operating cash flow was negative; this heightens refinancing dependence. Cash and deposits: +¥4.92bn (+34.3%) to ¥19.25bn - headline liquidity improved, but the increase was primarily supported by ¥7.15bn of financing cash inflow rather than internal cash generation. Accounts receivable: +¥8.17bn (+14.1%) to ¥66.16bn - receivables are 51.8% of total assets and consumed operating cash; collection performance and DSO are critical. Inventories: +¥1.39bn (+10.2%) to ¥14.99bn - inventory growth added to working-capital absorption and should be monitored against sales growth and turnover. Accounts payable: +¥7.84bn (+13.0%) to ¥67.95bn - supplier credit partly financed higher receivables and inventories, increasing sensitivity to payment terms. Total equity: -¥0.19bn (-0.9%) to ¥20.29bn - positive attributable profit was more than offset by unfavorable comprehensive-income movements, limiting deleveraging capacity.

Cash Flow Quality

Cash-flow quality was weak in FY2026 Q2. Operating cash flow was negative ¥1.628bn despite ¥0.387bn of net income, resulting in an OCF/net income ratio of negative 4.21x and clearly breaching the 0.8x earnings-quality threshold. Cash conversion, measured as OCF/EBITDA, was negative 1.08x, confirming that EBITDA did not translate into operating cash. The principal driver was working-capital absorption rather than a reported loss. Trade receivables increased ¥8.185bn, inventories increased ¥1.386bn and other current assets increased ¥0.846bn. The increase in trade payables of ¥7.839bn offset much of the outflow, but not enough to prevent negative operating cash flow. Receivables were ¥66.16bn, equivalent to 51.8% of total assets, and the reported DSO of 81 days exceeds the 60-day warning level. The combination of rising receivables, rising inventories and reliance on higher payables is a key working-capital risk: continued sales growth can consume cash if collection timing and inventory turns do not improve. The reported accruals ratio of 1.6% is low, which is favorable in isolation, but it does not offset the negative cash realization in this period. Investing cash flow was negative ¥0.605bn, including capital expenditure of ¥0.318bn and intangible-asset purchases of ¥0.071bn. Free cash flow was negative ¥2.233bn. CapEx/depreciation was 0.35x, below the 0.7x underinvestment threshold; while this supports short-term liquidity, it may constrain replacement investment and operating capability if sustained. Financing cash flow of ¥7.149bn, primarily from ¥8.131bn of net short-term borrowing, more than financed the negative free cash flow and raised period-end cash. This debt-funded cash build is not equivalent to an improvement in cash-generation capacity. Cash-flow normalization requires improved receivable collection, disciplined inventory management and a reduction in dependence on short-term borrowing to fund the operating cycle.

Dividend Sustainability

No interim dividend was paid for FY2026 Q2. The full-year forecast DPS of ¥20 implies a dividend payout ratio of approximately 34.2% based on forecast EPS of ¥58.46, which is moderate on an earnings basis. The implied full-year cash dividend requirement is approximately ¥0.445bn based on 22.24 million issued shares. Forecast attributable profit of ¥1.30bn would cover this dividend by roughly 2.9x. However, first-half operating cash flow was negative ¥1.628bn and free cash flow was negative ¥2.233bn, so cash coverage is presently weaker than accounting-profit coverage. The company paid ¥0.443bn of cash dividends during the period, broadly equivalent to the forecast annual dividend amount, while also relying on increased short-term loans. There is no reported share-buyback activity of significance, so payout analysis is appropriately focused on dividends rather than total shareholder return. Dividend sustainability depends on second-half working-capital release and restored positive operating cash flow rather than solely on achieving forecast net income. The modest forecast payout ratio provides flexibility, but elevated leverage and refinancing needs should remain higher capital-allocation priorities than increasing distributions.

Risk Assessment

Business risks include Margin risk: gross margin declined to 11.6% and operating margin to 0.39%; in a high-volume medical distribution model, small procurement-price, reimbursement, product-mix or logistics-cost changes can materially affect profit., Working-capital execution risk: receivables rose ¥8.185bn, inventories rose ¥1.386bn and reported DSO was 81 days, making cash generation highly sensitive to collection and inventory turnover., Forecast execution risk: operating-income progress of 33.4% is 16.6 percentage points below the normal Q2 run rate, requiring a pronounced second-half earnings recovery., Industry-specific healthcare distribution risk: pricing pressure from medical institutions, supplier terms and changes in healthcare reimbursement conditions can compress already narrow distributor margins., Asset-return risk: small impairment losses were recognized in the medical-device sales and care/welfare businesses, requiring monitoring of returns on operating assets in these activities..

Financial risks include High leverage: D/E of 5.29x and debt/EBITDA of 19.18x indicate aggressive debt use relative to the current earnings base., Refinancing risk: 86.0% of interest-bearing debt is short term, while cash covers only 0.78x of short-term debt., Liquidity risk: the quick ratio is 92.4%, below 1.0x, and negative operating cash flow increases dependence on bank funding and working-capital management., Cash-conversion risk: OCF/net income was negative 4.21x and free cash flow was negative ¥2.233bn., Tax burden risk: the 51.7% effective tax rate reduced net-income conversion and may continue to depress earnings if not normalized..

Key concerns include Highest priority is the interaction of weak operating margins, negative cash conversion and expanding short-term debt., The increase in cash deposits was financed by borrowing, not recurring cash flow, so headline cash growth does not reduce underlying funding risk., The reported annualized ROE of 3.8% is low despite 6.29x financial leverage, indicating limited returns on the operating asset base., CapEx/depreciation of 0.35x supports near-term cash preservation but may create maintenance or capability risk if investment remains below depreciation for an extended period., Goodwill-related impairment risk is limited at present because goodwill is only 5.2% of equity and 0.70x EBITDA..

Investment Implications

Key takeaways include Revenue growth remains intact, but gross-margin compression caused operating income to decline 22.1% YoY., The company must deliver a significant second-half recovery to achieve its operating-income and attributable-profit forecasts., Negative operating cash flow was driven by working-capital absorption and financed through increased short-term borrowing., Balance-sheet risk is elevated because D/E is 5.29x, debt/EBITDA is 19.18x and 86.0% of debt is short term., Goodwill and intangible-asset exposure are modest, reducing M&A accounting and impairment dependence., The forecast dividend payout ratio is moderate, but future cash distributions depend on cash-flow normalization..

Metrics to watch include Gross margin and operating margin recovery, Second-half operating-income progress versus the ¥1.75bn full-year forecast, Trade receivables, DSO and inventory growth relative to sales, Operating cash flow and free cash flow conversion, Short-term loan balance, cash-to-short-term-debt ratio and refinancing terms, Debt/EBITDA, D/E and interest coverage, CapEx/depreciation ratio and impairment activity in medical-device sales and care/welfare operations, Effective tax rate and conversion of ordinary income into attributable profit.

Regarding relative positioning, The company exhibits the profile of a low-margin healthcare distributor: asset turnover is comparatively strong at 2.338x, but profitability and cash generation are weak relative to standard corporate benchmarks. Its annualized ROE of 3.8% is below the 8% concern threshold despite substantial financial leverage, while debt/EBITDA of 19.18x and negative cash conversion create a more stressed financial profile than a conservatively funded distributor. Conversely, goodwill exposure is low and interest coverage remains above immediate distress levels, providing some offset to the leverage concern.